Grant: Catalyst Grant: Sex as a Variable in Biomedical Research
University of Toronto
$150,000.00
Sex-specific DNA methylation marks in VKORC1 and UBIAD1 as variables in clinical decision rules for recurrent VTE
EF 2017-18
Résumé
Venous thromboembolism (VTE) is a blood clot that forms in a vein. VTE is a common, lethal, costly, yet treatable condition. There are effective drugs to prevent VTE but they carry an increase risk of bleeding. Our team has long-term interest in understanding what causes VTE, and how to prevent and treat VTE. We argue that we need to understand how DNA and the way it is packaged and 'read' (i.e. the epigenetic 'code') lead to disease in order to better prevent and manage VTE. The epigenetic code is the intermediate player linking a person's environment and his/her genetic make up.
An individual's sex is an important variable on how the genetic and epigenetic codes impact a person's risk to VTE, and how he or she responds to treatment. In particular, we are intrigued by the fact that men and women have a similar risk of developing a first VTE, but men have more than twice the risk of a subsequent VTE after a 'blood thinner' drug treatment is stopped. We propose that sex-specific epigenetic marks underlie the protective effect against subsequent VTE observed in women after treatment with a 'blood thinner'.
We will analyze patients' blood sample, biological and clinical data, and perform lab experiments, to understand the biology behind sex differences in VTE treatment. This will be the basis of new tests that will ultimately improve the standard of care received by men and women after a first VTE event. Given the importance and the risk of using 'blood thinners' to manage patients following a VTE, being able to predict who will benefit the most from such drugs and who can safely discontinue their use after initial treatment are of major importance in caring for these patients. This will also inform on novel intervention targets that could reverse the risk of VTE.
Programme
Catalyst Grant: Sex as a Variable in Biomedical Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
377882
Name
Gagnon France
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Catalyst Grant: Sex as a Variable in Biomedical or Translational Research
Projecttitle
Sex-specific DNA methylation marks in VKORC1 and UBIAD1 as variables in clinical decision rules for recurrent VTE
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Sex as a Variable in Biomedical Research
Keyworddelim
Clinical Decision Rules; Epidemiology; Epigenomics; Genome Editing; Genomics; Sex Differences; Venous Thrombosis
Abstract
Venous thromboembolism (VTE) is a blood clot that forms in a vein. VTE is a common, lethal, costly, yet treatable condition. There are effective drugs to prevent VTE but they carry an increase risk of bleeding. Our team has long-term interest in understanding what causes VTE, and how to prevent and treat VTE. We argue that we need to understand how DNA and the way it is packaged and 'read' (i.e. the epigenetic 'code') lead to disease in order to better prevent and manage VTE. The epigenetic code is the intermediate player linking a person's environment and his/her genetic make up.
An individual's sex is an important variable on how the genetic and epigenetic codes impact a person's risk to VTE, and how he or she responds to treatment. In particular, we are intrigued by the fact that men and women have a similar risk of developing a first VTE, but men have more than twice the risk of a subsequent VTE after a 'blood thinner' drug treatment is stopped. We propose that sex-specific epigenetic marks underlie the protective effect against subsequent VTE observed in women after treatment with a 'blood thinner'.
We will analyze patients' blood sample, biological and clinical data, and perform lab experiments, to understand the biology behind sex differences in VTE treatment. This will be the basis of new tests that will ultimately improve the standard of care received by men and women after a first VTE event. Given the importance and the risk of using 'blood thinners' to manage patients following a VTE, being able to predict who will benefit the most from such drugs and who can safely discontinue their use after initial treatment are of major importance in caring for these patients. This will also inform on novel intervention targets that could reverse the risk of VTE.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gagnon, France; Rodger, Marc A; Wilson, Michael D
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $75,000~ $0~Inst of Gender & Health~ $75,000~ $0~